Aug 20, 2021 09:14 AM (GMT+8) · EqualOcean
CICC said that due to the continuous pressure of generic drugs affected by centralized purchase and the decline of core product sales, Hengrui pharmaceutical's performance in the first half of the year was lower than expected, lowered the company's profit forecast and target price, and maintained the outperformance industry rating. The forecast of net profit attributable to parent company for 2021 / 2022 was lowered by 19.3% / 29.4% to RMB 6.522/6.851 billion; Maintain the outperformance rating of the industry and reduce the target price by 33.3% to 80.00 yuan.

This text is a result of machine translation.